ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC

Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics

Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus

Sanofi to acquire Kadmon to further strengthen growth of transplant business

Dupixent® (dupilumab) efficacy and quality of life data in asthma patients across multiple age groups to be presented at 2021 ERS international congress

Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months

FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease

Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer

Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development

Online availability of Sanofi’s half-year financial report for 2021